Home › Funds › LOS ANGELES CAPITAL MANAGEMENT LLC › REGN

LOS ANGELES CAPITAL MANAGEMENT LLC position in REGN

REGENERON PHARMACEUTICALS · Health Care

LOS ANGELES CAPITAL MANAGEMENT LLC reported holding 266,469 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$202.1M, representing 0.69% of its reported portfolio and ranking #25 among its reported holdings. LOS ANGELES CAPITAL MANAGEMENT LLC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)266.47K sh
Reported value held$202.06M
Portfolio Weight0.69%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How LOS ANGELES CAPITAL MANAGEMENT LLC's REGN position evolved

LOS ANGELES CAPITAL MANAGEMENT LLC first disclosed a stake in REGN in Q3 2023 at 700 shares (US$576K). The position peaked in Q3 2026 at 266,469 shares, worth US$202.1M. Across 13 filings, LOS ANGELES CAPITAL MANAGEMENT LLC increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 266,469 shares valued at US$202.1M — an increase of 167,884 shares quarter over quarter.. Notable position changes include a 664% increase in Q4 2023 (shares rose 10% over the following quarter), a 1376% increase in Q1 2025 (shares fell 17% over the following quarter), a 1187% increase in Q3 2025 (shares rose 36% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 700 $576.07K New
Q4 2023 5.34K $4.69M Add
Q1 2024 1.24K $1.20M Reduce
Q2 2024 2.53K $2.66M Add
Q3 2024 1.76K $1.85M Reduce
Q4 2024 526 $374.69K Reduce
Q1 2025 7.76K $4.92M Add
Q2 2025 7.41K $3.89M Reduce
Q3 2025 95.33K $53.60M Add
Q4 2025 100.51K $65.74M Add
Q1 2026 78.88K $60.95M Reduce
Q2 2026 98.58K $61.47M Add
Q3 2026 266.47K $202.06M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has LOS ANGELES CAPITAL MANAGEMENT LLC held REGN?

LOS ANGELES CAPITAL MANAGEMENT LLC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is LOS ANGELES CAPITAL MANAGEMENT LLC's current position in REGN?

As of Q3 2026, LOS ANGELES CAPITAL MANAGEMENT LLC holds 266.47K shares of REGN (REGENERON PHARMACEUTICALS), valued at $202.06M, representing 0.69% of its reported portfolio and ranking #25.

Has LOS ANGELES CAPITAL MANAGEMENT LLC been buying or selling REGN?

In the latest 13F filing (Q3 2026), LOS ANGELES CAPITAL MANAGEMENT LLC increased its position in REGN. The position peaked in Q3 2026 at 266.47K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.